Berliner Boersenzeitung - Ozempic-maker Novo Nordisk says CEO to step down

EUR -
AED 4.243698
AFN 80.258838
ALL 97.948582
AMD 440.593622
ANG 2.067968
AOA 1058.468643
ARS 1362.808871
AUD 1.778291
AWG 2.082849
AZN 1.967714
BAM 1.955772
BBD 2.322866
BDT 140.587965
BGN 1.960516
BHD 0.433994
BIF 3425.45041
BMD 1.155533
BND 1.477579
BOB 7.949885
BRL 6.406162
BSD 1.150483
BTN 98.998567
BWP 15.463776
BYN 3.764945
BYR 22648.45212
BZD 2.310967
CAD 1.569965
CDF 3324.469025
CHF 0.938799
CLF 0.027885
CLP 1070.054509
CNY 8.298584
CNH 8.307603
COP 4778.730819
CRC 579.891605
CUC 1.155533
CUP 30.621632
CVE 110.263404
CZK 24.845004
DJF 204.867034
DKK 7.461298
DOP 67.949016
DZD 150.258825
EGP 57.439168
ERN 17.332999
ETB 155.208653
FJD 2.597927
FKP 0.851375
GBP 0.852446
GEL 3.166005
GGP 0.851375
GHS 11.849828
GIP 0.851375
GMD 81.461235
GNF 9968.855682
GTQ 8.840872
GYD 240.696515
HKD 9.07026
HNL 30.026565
HRK 7.537198
HTG 150.877816
HUF 402.709136
IDR 18834.383451
ILS 4.183495
IMP 0.851375
INR 99.589054
IQD 1507.078182
IRR 48647.950422
ISK 144.036987
JEP 0.851375
JMD 184.197333
JOD 0.819252
JPY 166.519309
KES 148.637848
KGS 101.051741
KHR 4612.933219
KMF 492.828034
KPW 1039.979937
KRW 1579.775544
KWD 0.353847
KYD 0.958686
KZT 590.091457
LAK 24822.640644
LBP 103081.107701
LKR 344.475013
LRD 230.096669
LSL 20.7043
LTL 3.411989
LVL 0.698971
LYD 6.285909
MAD 10.518948
MDL 19.701715
MGA 5194.924793
MKD 61.534109
MMK 2426.276265
MNT 4138.7804
MOP 9.301065
MRU 45.673339
MUR 52.588202
MVR 17.80096
MWK 1994.87112
MXN 21.898222
MYR 4.905816
MZN 73.896841
NAD 20.7043
NGN 1782.340361
NIO 42.339387
NOK 11.454573
NPR 158.397707
NZD 1.920463
OMR 0.444024
PAB 1.150483
PEN 4.15254
PGK 4.80593
PHP 64.813692
PKR 326.154978
PLN 4.273527
PYG 9179.867104
QAR 4.196739
RON 5.02714
RSD 117.198303
RUB 92.187365
RWF 1661.27595
SAR 4.337402
SBD 9.645688
SCR 16.420422
SDG 693.891475
SEK 10.959072
SGD 1.481277
SHP 0.908068
SLE 25.479798
SLL 24230.959169
SOS 657.490482
SRD 43.36485
STD 23917.205706
SVC 10.066854
SYP 15024.073349
SZL 20.6907
THB 37.445019
TJS 11.619632
TMT 4.044366
TND 3.404151
TOP 2.70638
TRY 45.531801
TTD 7.801887
TWD 34.111103
TZS 2973.956946
UAH 47.721109
UGX 4145.939979
USD 1.155533
UYU 47.299315
UZS 14617.788379
VES 118.057382
VND 30130.530052
VUV 137.626518
WST 3.026557
XAF 655.947504
XAG 0.031814
XAU 0.000336
XCD 3.122886
XDR 0.815788
XOF 655.947504
XPF 119.331742
YER 281.198547
ZAR 20.713338
ZMK 10401.192896
ZMW 27.812597
ZWL 372.081242
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Ozempic-maker Novo Nordisk says CEO to step down
Ozempic-maker Novo Nordisk says CEO to step down / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File

Ozempic-maker Novo Nordisk says CEO to step down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Text size:

The company said the decision was made by mutual agreement with the board and that it was searching for a successor for Lars Fruergaard Jorgensen.

Jorgensen will continue "for a period to support a smooth transition to new leadership", Novo Nordisk said in a statement.

The change is being made "in light of the recent market challenges Novo Nordisk has been facing and the development of the company's share price since mid-2024", it said.

At the same time, the company stressed the success it had seen under Jorgensen's stewardship.

"During his eight-year tenure as CEO, Novo Nordisk's sales, profits and share price have almost tripled," Novo Nordisk said.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago.

Ozempic, which accounts for 41 percent of Novo Nordisk's sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Novo Nordisk launched the anti-obesity drug Wegovy, which uses the same molecule but has been directly approved as a weight loss treatment, in the United States in 2021.

Following the success of its treatments, Novo Nordisk rose to become Europe's most valuable company by market capitalisation in September 2023, overtaking French luxury fashion house LVMH, making the company a cornerstone of the Danish economy.

The drugmaker has since been dethroned and reclaimed the spot several times, having last been overtaken for the lead by German tech company SAP in March.

- Facing competition -

Since June 2024, Novo Nordisk's share has fallen by more than half and now ranks as Europe's fourth most valuable company.

The share price dropped more than three percent on the Copenhagen stock exchange following Friday's announcement.

The decline has come as its dominant position has faced several challenges.

Earlier this month, the company cut its full-year sales growth forecast due to competition from copycat versions of its popular GLP-1 injections made in US pharmacies -- a practice known as compounding.

The pharmacies had been allowed to make their own version of Wegovy and Ozempic due to a shortage of the drugs.

But US regulators ruled in February that the shortage had ended and ordered pharmacies to discontinue making the compounded versions.

"We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments," Jorgensen said in a statement in early May.

The Danish group had cut its sales forecast from the 16-to-24 percent range to 13-to-21 percent.

Novo Nordisk is also facing competition from US rival Eli Lilly, which makes the anti-obesity injection Zepbound.

Novo Nordisk's shares tumbled last month after Eli Lilly announced a successful clinical trial of diabetes and obesity treatment orforglipron.

Around the world, more than 10 percent of the population suffers from diabetes, for which treatments make up the core of the drugmaker's business.

According to the International Diabetes Federation, the number of diabetic adults is expected to increase by 46 percent by 2045.

The World Obesity Federation also predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.

(A.Lehmann--BBZ)